Working… Menu

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02554773
Recruitment Status : Active, not recruiting
First Posted : September 18, 2015
Last Update Posted : October 20, 2021
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2023